Table 2 Orphan drugs with highest number of users, highest prices and highest budget impact (2012)
From: Orphan drugs expenditure in the Netherlands in the period 2006–2012
Rank | INN | Trade name | Setting | Patients | |
|---|---|---|---|---|---|
1 | Imatinib | Glivec® | Outpatient | 1,485 | |
2 | Lenalidomide | Revlimid® | Outpatient | 1,089 | |
3 | Sildenafil | Revatio® | Outpatient | 1,052 | |
4 | Thalidomide | Thalidomide Cellgene® | Outpatient | 1,030 | |
5 | Bosentan | Tracleer® | Outpatient | 901 | |
Rank | INN | Trade name | Setting | Cost/Patient | |
1 | Galsulfase | Naglazyme® | Inpatient | €600,000 | |
1 | Idursulfase | Elaprase® | Inpatient | €600,000 | |
3 | Alglucosidase alfa | Myzoyme® | Inpatient | €474,857* | |
4 | Eculizumab | Soliris® | Inpatient | €358,000 | |
5 | Aldurazyme | Laronidase® | Inpatient | €300,000 | |
Rank | INN | Trade name | Setting | Budget impact (millions) | Cumulative budget impact 2006–2012 (millions) |
1 | Alglucosidase alfa | Myozyme® | Inpatient | €40.3 | €203.4 |
2 | Imatinib | Glivec® | Outpatient | €36.4 | €251.2 |
3 | Lenalidomide | Revlimid® | Outpatient | €36.2 | €127.4 |
4 | Bosentan | Tracleer® | Outpatient | €23.0 | €132.4 |
5 | Pegvisomant | Somavert® | Outpatient | €14.3 | €72.5 |